JP2003517432A - プラバスタチンナトリウム含有薬剤組成物 - Google Patents

プラバスタチンナトリウム含有薬剤組成物

Info

Publication number
JP2003517432A
JP2003517432A JP2000540858A JP2000540858A JP2003517432A JP 2003517432 A JP2003517432 A JP 2003517432A JP 2000540858 A JP2000540858 A JP 2000540858A JP 2000540858 A JP2000540858 A JP 2000540858A JP 2003517432 A JP2003517432 A JP 2003517432A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pravastatin sodium
cyclodextrin
stability
magnesium stearate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000540858A
Other languages
English (en)
Japanese (ja)
Inventor
チャン，マン，シク
リム，ヲーン，スプ
スー，セウン，ヲン
チャ，ジュング，クヲン
リー，ジュン，ミン
キム，ジュン，ジョオ
カン，タエ，スク
Original Assignee
ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド filed Critical ユン ジン ファーマスーチカル インダストリーズ カンパニー リミテッド
Publication of JP2003517432A publication Critical patent/JP2003517432A/ja
Pending legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2000540858A 1998-03-31 1999-03-31 プラバスタチンナトリウム含有薬剤組成物 Pending JP2003517432A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1998/11172 1998-03-31
KR1019980011172A KR100281521B1 (ko) 1998-03-31 1998-03-31 프라바스타틴나트륨이 함유된 약제 조성물
PCT/KR1999/000157 WO1999049896A1 (en) 1998-03-31 1999-03-31 A drug composition containing sodium pravastatin

Publications (1)

Publication Number Publication Date
JP2003517432A true JP2003517432A (ja) 2003-05-27

Family

ID=19535615

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000540858A Pending JP2003517432A (ja) 1998-03-31 1999-03-31 プラバスタチンナトリウム含有薬剤組成物

Country Status (7)

Country Link
EP (1) EP1067967A1 (ko)
JP (1) JP2003517432A (ko)
KR (1) KR100281521B1 (ko)
CN (1) CN1298311A (ko)
AU (1) AU3057099A (ko)
CA (1) CA2326603A1 (ko)
WO (1) WO1999049896A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4658306B2 (ja) * 2000-10-18 2011-03-23 ナガセ医薬品株式会社 錠剤用医薬組成物
WO2003055991A1 (en) * 2001-12-21 2003-07-10 Rigshospitalet Igamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux
EP1490029A4 (en) * 2002-03-22 2006-02-22 Ranbaxy Lab Ltd DRUG DELIVERY SYSTEM WITH CONTROLLED RELEASE OF PRAVASTATIN
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
WO2007016757A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
US7879821B2 (en) * 2006-01-26 2011-02-01 University Of Medicine And Dentistry Of New Jersey Method for modulating inflammatory responses by altering plasma lipid levels
BG934U1 (bg) * 2006-12-14 2007-11-30 "Софарма" Ад Състав за твърда лекарствена форма, съдържащ правастатин
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
CN101580466B (zh) * 2008-05-12 2012-04-04 上海天伟生物制药有限公司 一种萘维太定的钠盐的制备方法
JP4890657B1 (ja) * 2011-06-03 2012-03-07 小野薬品工業株式会社 リマプロストとβ−シクロデキストリンを含有する錠剤
JP6088872B2 (ja) * 2013-03-22 2017-03-01 サラヤ株式会社 ラクトン型ソホロリピッドの分解が抑制されたソホロリピッド粉末

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3223232C2 (de) * 1982-06-22 1984-04-05 Wolfgang Dipl.-Phys. Dr.-Ing. 4800 Bielefeld Lindemann Vorschubeinrichtung an einer mit einem umlaufenden Werkzeug versehenen Maschine, wie Schäl- oder Richtmaschine, für stangenförmiges Material, wie Wellen, Draht, Rohre o.dgl.
DD232198A1 (de) * 1984-07-13 1986-01-22 Jenapharm Veb Verfahren zur herstellung von festen komprimaten
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
TW224049B (ko) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013147488A (ja) * 2011-12-21 2013-08-01 Taisho Pharmaceutical Co Ltd 固形製剤

Also Published As

Publication number Publication date
WO1999049896A1 (en) 1999-10-07
AU3057099A (en) 1999-10-18
EP1067967A1 (en) 2001-01-17
CN1298311A (zh) 2001-06-06
CA2326603A1 (en) 1999-10-07
KR100281521B1 (ko) 2001-02-15
KR19990076302A (ko) 1999-10-15

Similar Documents

Publication Publication Date Title
US6936274B2 (en) Storage stable thyroxine active drug formulations and methods for their production
EP3302565B1 (en) Solid dosage forms of palbociclib
TW492878B (en) Tablet composition
EP0508756B1 (en) Stabilized vitamin D preparation
HUE031227T2 (en) Dry granulation process for preparing metformin tablet compositions and compositions thereof
HU230395B1 (hu) Levodopa /carbidopa/ entacapone tartalmú orálisan adagolható szilárd készítmény, eljárás ennek előállítására és ezt tartalmazó tabletta
JP2003517432A (ja) プラバスタチンナトリウム含有薬剤組成物
US7052717B2 (en) Storage stable thyroxine active drug formulations and methods for their production
JP2005314413A (ja) 経口投与用医薬組成物
KR101504862B1 (ko) 리마프로스트와 β-시클로덱스트린을 함유하는 정제
US20090298944A1 (en) Pharmaceutical composition
JP2814513B2 (ja) 溶出性の改良された製剤組成物
JP5922310B2 (ja) 医薬製剤
JP3037393B2 (ja) 経口投与用固形薬剤の製造方法
AU657044B2 (en) Cytarabine ocfosfate hard capsule
US20110262540A1 (en) Solid Pharmaceutical Composition Comprising Exemestane
JP2006022040A (ja) 高い安定性を有するシンバスタチン固形製剤
TWI252755B (en) Medical composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid
JP2003160474A (ja) 難溶性薬物含有固形製剤の製造方法
WO1999020277A1 (fr) Composition medicamenteuse a dissolution rapide
KR100514590B1 (ko) 프라바스타틴나트륨 및 안정화제로서의 코폴리비돈을함유하는 약제 조성물
KR20200074046A (ko) 톨밥탄을 포함하는 고체분산체 제조를 위한 약제학적 조성물 및 이의 제조방법
WO2006016602A1 (ja) 苦味の低減したナテグリニド含有製剤
JP2024004706A (ja) 医薬組成物及び医薬製剤
JPH09263536A (ja) テルフェナジンを含有する医薬組成物

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050705